428 related articles for article (PubMed ID: 37249862)
1. Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Mekala JR; Adusumilli K; Chamarthy S; Angirekula HSR
Metab Brain Dis; 2023 Aug; 38(6):1801-1829. PubMed ID: 37249862
[TBL] [Abstract][Full Text] [Related]
2. Targeting Non-coding RNA for Glioblastoma Therapy: The Challenge of Overcomes the Blood-Brain Barrier.
Sharma RK; Calderon C; Vivas-Mejia PE
Front Med Technol; 2021; 3():678593. PubMed ID: 35047931
[TBL] [Abstract][Full Text] [Related]
3. New insights for precision treatment of glioblastoma from analysis of single-cell lncRNA expression.
Meng Q; Zhang Y; Li G; Li Y; Xie H; Chen X
J Cancer Res Clin Oncol; 2021 Jul; 147(7):1881-1895. PubMed ID: 33693962
[TBL] [Abstract][Full Text] [Related]
4. Non-coding RNAs enhance the apoptosis efficacy of therapeutic agents used for the treatment of glioblastoma multiform.
Ghaemi S; Fekrirad Z; Zamani N; Rahmani R; Arefian E
J Drug Target; 2022 Jul; 30(6):589-602. PubMed ID: 35282758
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA MALAT1 as a key target in pathogenesis of glioblastoma. Janus faces or Achilles' heal?
Baspinar Y; Elmaci I; Ozpinar A; Altinoz MA
Gene; 2020 May; 739():144518. PubMed ID: 32119915
[TBL] [Abstract][Full Text] [Related]
6. Modulating lncRNA SNHG15/CDK6/miR-627 circuit by palbociclib, overcomes temozolomide resistance and reduces M2-polarization of glioma associated microglia in glioblastoma multiforme.
Li Z; Zhang J; Zheng H; Li C; Xiong J; Wang W; Bao H; Jin H; Liang P
J Exp Clin Cancer Res; 2019 Aug; 38(1):380. PubMed ID: 31462285
[TBL] [Abstract][Full Text] [Related]
7. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
[TBL] [Abstract][Full Text] [Related]
9. [Dysregulation of Long Non-coding RNAs in Glioblastoma Multiforme and Their Study Through Use of Modern Molecular-Genetic Approaches].
Večeřa M; Šána J; Bútová R; Reguli Š; Hermanová M; Křen L; Lipina R; Smrčka M; Slabý O
Klin Onkol; 2018; 31(Supplementum1):168-170. PubMed ID: 29808696
[TBL] [Abstract][Full Text] [Related]
10. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
[TBL] [Abstract][Full Text] [Related]
11. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
12. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
13. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.
Shea A; Harish V; Afzal Z; Chijioke J; Kedir H; Dusmatova S; Roy A; Ramalinga M; Harris B; Blancato J; Verma M; Kumar D
Cancer Med; 2016 Aug; 5(8):1917-46. PubMed ID: 27282910
[TBL] [Abstract][Full Text] [Related]
15. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
[TBL] [Abstract][Full Text] [Related]
16. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
17. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against Glioblastoma Multiforme.
Janaki Ramaiah M; Divyapriya K; Kartik Kumar S; Rajesh YBRD
Gene; 2020 Jan; 723():144126. PubMed ID: 31589963
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT.
Zhao C; Guo R; Guan F; Ma S; Li M; Wu J; Liu X; Li H; Yang B
Sci Rep; 2020 Jun; 10(1):9471. PubMed ID: 32528036
[TBL] [Abstract][Full Text] [Related]
20. Construction of lncRNA-associated ceRNA networks to identify prognostic lncRNA biomarkers for glioblastoma.
Liu Z; Wang X; Yang G; Zhong C; Zhang R; Ye J; Zhong Y; Hu J; Ozal B; Zhao S
J Cell Biochem; 2020 Jul; 121(7):3502-3515. PubMed ID: 32277520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
